PADI4 and peripheral arterial disease: The current study was aimed at encapsulating the pan-PAD inhibitor Cl-amidine into P(3HB) microspheres for controlled drug delivery, which may be applicable in a range of PAD-related pathologies, including inflammatory, autoimmune and neurodegenerative diseases, as well as cancer.